PRECIGEN, INC.
PGENNasdaq
$4.95
0.0%Jul 17 close · end-of-day
Price
1Y↑ +169.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.8B
Enterprise Value
$1.8B
P/E
—
P/S
—
P/B
86.7
EV/EBITDA
—
PEG
—
FCF Yield
-6.7%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$204.4M
Free Cash Flow (TTM)
-$117.0M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-1010.0%
ROIC
—
Debt / Equity
4.6
Net Cash
-$37.3M
Return 1Y
+172.0%
Company profile
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. The company was formerly known as Intrexon Corporation and changed its name to Precigen in January 2020.
- CEO
- Helen Sabzevari
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 190
- Headquarters
- Maryland
- Website
- precigen.com
Management & directors
- Thomasian Harry Jr.Chief Financial Officer
- Sabzevari HelenPresident and CEO
- Shah Rutul RChief Operating Officer
- Lehr Donald P.Chief Legal Officer
- Tennant PhilChief Commercial Officer
Roles derived from SEC Form 4 filings.
Earnings
PGEN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$23.3M↑ +1633.9%
Diluted EPS-$0.02↓ -88.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $32.0M | $14.3M | $26.9M | $6.2M | $3.9M | $9.7M |
| Gross profit | — | — | — | — | — | — |
| Operating income | — | — | — | -$99.8M | -$135.0M | -$110.5M |
| Net income | -$170.5M | -$92.2M | $28.3M | -$95.9M | -$126.2M | -$250.6M |
| Diluted EPS | -$1.02 | -$0.47 | $0.14 | -$0.39 | -$0.47 | -$1.37 |
| Operating cash flow | -$77.0M | -$55.8M | -$65.0M | -$66.9M | -$68.2M | -$87.8M |
| Free cash flow | -$84.5M | -$63.0M | -$70.0M | -$68.5M | -$76.8M | -$89.8M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | -1602.5% | -3440.2% | -1141.1% |
| Net margin | -533.0% | -646.2% | 105.2% | -1540.6% | -3215.3% | -2587.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $1.3M | — | — | — | $23.3M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | -$22.6M | — | — | — | -$6.0M |
| Net income | -$58.8M | -$24.0M | -$19.7M | -$54.2M | -$26.6M | -$146.3M | -$23.5M | -$7.9M |
| Diluted EPS | -$0.23 | -$0.09 | -$0.05 | -$0.18 | -$0.09 | -$1.06 | -$0.04 | -$0.02 |
| Operating cash flow | -$23.1M | -$22.7M | -$8.2M | -$16.3M | -$19.0M | -$29.1M | -$23.5M | -$43.8M |
| Free cash flow | -$25.4M | -$23.6M | -$9.3M | -$16.9M | -$19.9M | -$29.5M | -$23.5M | -$44.1M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | -1685.0% | — | — | — | -25.8% |
| Net margin | — | — | — | -4038.3% | — | — | — | -34.1% |
Company news
Jul 15, 2026
Jun 23, 2026
Jun 20, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-01 | Thomasian Harry Jr.· Chief Financial Officer | Sale | 171,429 | $5.53 | $948,002.37 | filing |
| 2026-06-29 | Sabzevari Helen· President and CEO | Sale | 346,836 | $5.89 | $2.0M | filing |
| 2026-06-29 | Sabzevari Helen· President and CEO | Option exercise | 346,836 | $2.33 | $808,127.88 | filing |
| 2026-06-29 | Shah Rutul R· Chief Operating Officer | Sale | 42,924 | $5.85 | $251,105.40 | filing |
| 2026-06-29 | Thomasian Harry Jr.· Chief Financial Officer | Sale | 28,571 | $5.78 | $165,140.38 | filing |
| 2026-06-29 | Shah Rutul R· Chief Operating Officer | Option exercise | 42,924 | $2.33 | $100,012.92 | filing |
| 2026-05-28 | Sabzevari Helen· President and CEO | Sale | 119,250 | $4.36 | $519,930.00 | filing |
| 2026-05-28 | Shah Rutul R· Chief Operating Officer | Sale | 42,703 | $4.36 | $186,185.08 | filing |
| 2026-05-28 | Thomasian Harry Jr.· Chief Financial Officer | Sale | 41,884 | $4.36 | $182,614.24 | filing |
| 2026-05-28 | Tennant Phil· Chief Commercial Officer | Sale | 30,272 | $4.36 | $131,985.92 | filing |
| 2026-05-28 | Lehr Donald P.· Chief Legal Officer | Sale | 29,131 | $4.36 | $127,011.16 | filing |
| 2026-05-23 | Shah Rutul R· Chief Operating Officer | Option exercise | 90,000 | — | — | filing |
| 2026-05-23 | Thomasian Harry Jr.· Chief Financial Officer | Option exercise | 87,500 | — | — | filing |
| 2026-05-23 | Tennant Phil· Chief Commercial Officer | Option exercise | 62,500 | — | — | filing |
| 2026-05-23 | Sabzevari Helen· President and CEO | Option exercise | 250,000 | — | — | filing |
| 2026-05-23 | Lehr Donald P.· Chief Legal Officer | Option exercise | 62,500 | — | — | filing |
| 2026-03-30 | KIRK RANDAL J | Sale | 2,334,420 | $3.30 | $7.7M | filing |
| 2026-03-30 | KIRK RANDAL J | Sale | 1,108,998 | $3.30 | $3.7M | filing |
| 2026-03-30 | KIRK RANDAL J | Sale | 426,199 | $3.30 | $1.4M | filing |
| 2026-03-30 | KIRK RANDAL J | Sale | 370,847 | $3.30 | $1.2M | filing |
| 2026-03-30 | KIRK RANDAL J | Sale | 168,794 | $3.30 | $557,020.20 | filing |
| 2026-03-30 | KIRK RANDAL J | Sale | 152,063 | $3.30 | $501,807.90 | filing |
| 2026-03-30 | KIRK RANDAL J | Sale | 50,797 | $3.30 | $167,630.10 | filing |
| 2026-03-30 | KIRK RANDAL J | Sale | 50,797 | $3.30 | $167,630.10 | filing |
| 2026-03-30 | KIRK RANDAL J | Sale | 47,101 | $3.30 | $155,433.30 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.